Abstract
BACKGROUND: Rhabdomyosarcoma (RMS) of the extremities has a particularly poor prognosis compared to other primary sites due to an increased rate of alveolar histology, higher rate of metastasis, and the extent of regional lymph node involvement. To date there are few assessments comparing upper extremity (UE) to lower extremity (LE) RMS of the extremities using population-based registry, so we sought to compare survival between UE and LE RMS. MATERIALS AND METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, cases of RMS of the UE and LE diagnosed between 2000-2020 were collected. Descriptive statistics and chi-square analyses were completed for one-and five-year survival. Log-rank and Cox regression analyses were completed to compare UE versus LE survival. RESULTS: A total of 641 cases were included, of which 221 (34.5%) were UE and 420 (65.5%) were LE. On log-rank tests, UE survival was longer than LE survival (p = 0.021). The one-year survival rate was greater for the UE (88.7%) compared to the LE (81.4%) (p = 0.020) but similar at five-years. Cox regression analysis showed no difference in survival between UE and LE primary site (hazard ratio = 1.172, p = 0.322). CONCLUSIONS: In comparing UE and LE RMS survival, UE survival was greater at one-year, but not on adjusted analyses. These findings contribute to the few prior assessments of outcomes between UE and LE RMS, though direct comparisons between UE and LE should be included in future prospective studies.